Hemcheck Sweden AB has gotten its patent application regarding the filter solution to receive and separate plasma from whole blood approved by the USPTO.
–It’s very positive that we have gotten this patent granted in the US since it protects a vital part of our technology which enables the fast hemolysis detection in blood samples. The patent has earlier been granted in Sweden and is currently under evaluation by the European patent office regarding the rest of the European market. The US market is the largest single market globally, hence this patent is very important for the company, says Hemcheck’s CEO Joen Averstad.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolyzed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analysed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolyzed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on December 17, 2020 at 20.30